Quellen

Nationales Referenzzentrum für Invasive Pilzinfektionen (www..nrz-myk.de/invasive-mykosen.html). Abgerufen am 09.07.2019.

Lanternier F, Dannaoui E, Morizot G, Ellie C, Garnia-Hermoso D, Huerre M, Bitar D, Dromer F, Lortholary O; French Mycosis Study Group. A global analysis of mucormycosis in France: the RetroZygo Study (2005- 2007). Clin Infect Dis 2012a; 54(Suppl 1):S35-43.

Skiada A, Lantemier F, Groll AH, Pagano L, Zimmerli S, Herbrecht R, Lortholary O, Petrikkos GL; European Conference on lnfections in Leukemia. Diagnosis and treatment of mucormycosis in patients with hematological malignancies: guidelines from the 3rd European Conference on lnfections in Leukemia (ECIL 3). Haematologica 2013;98(4):492- 504.

Petrikkos G, Skiada A, Lortholary O, Roilides E, Walsh TJ , Kontoyiannis DP. Epidemiollogy and Clinical Manifestations of Mucormycosis. Clin lnfect Dis 2012;54(Suppl 1):s23- 34.

Gesetze im Internet (https://www.gesetze-im-internet.de/ifsg/_6.html). Abgerufen am 09.07.2019

Skiada A, Pagano L, Groll A, Zimmerli S, Dupont B, Lagrou K, Lass-Flörl C, Bouza E, Klimko N, Gaustad P, Richardson M, Hamal P, Akova M, Meis JF, Rodriguez-Tudela JL, Roilides E, Mitrousia-Ziouva A, Petrikkos G; European Confederation of Medical Mycology Working Group on Zygomycosis. Zygomycosis in Europe: analysis of 230 cases accrued by the registry of the European Confederation of Medical Mycology (ECMM) Working Group on Zygomycosis between 2005 and 2007. Clin Microbiol lnfect 2011;17(12):1859- 1867.

Dagenais TR, Keller NP. Pathogenesis of Aspergillus fumigatus in lnvasive Aspergillosis. Clin Microbiol Rev 2009;22(3):447-465.

Cox GM, Kauffman CA, Thomer AR. Mucormycosis (zygomycosis). In: Post T (Hrsg.). UpToDate. Waltham, Mass.: UpToDate; 2017. www.uptodate.com. Abgerufen am 02.08.2017.

Maschmeyer G, Haas A, Cornely OA. lnvasive aspergillosis: epidemiollogy, diagnosis and management in immunocompromised patients. Drugs 2007;·67(11 ):1567-1601.

lbrahim AS, Spellberg B, Walsh TJ et al. Pathogenesis of mucormycosis. Clin lnfect Dis. 2012;54 Suppl 1:S16-S22.

Spellberg B, Edwards Jr J, Ibrahim A. Novell perspectives on mucormycosis: pathophysiology, presentation, and management. Clin Microbiol Rev. 2005;18:556-569.

Lanternier F, Sun HY, Ribaud P, Singh N, Kontoyiannis DP, Lortholary O. Mucormycosis in organ and stem cell transplant recipients. Clin lnf ect Dis 2012b;54 (11):i1629-1636.

Ostrosky-Zeichner L, AI-Obaidi M. Invasive Fungal Infections in the Intensive Care Unit. Infect Dis Clin North Am 2017;31(3):475-487. 

Bassetti M et. al. Intensive care medicine research agenda on invasive fungal infection in critically ill patients. Intensiv Care Med. 2017; 43: 1225-1238.

Schauwvlieghe AFAD et al. lnvasive aspergillosis in patients admitted to the intensive care unit with severe influenza: a retrospective cohort study. Lancet Respir Med. 2018 Oct;6(10):782-792.

Ku YH et al. Higher mortality of severe influenza patients with probable aspergillosis tlhan those with and without other coinfections. J Formos Med Assoc. 2017 Sep;H6(9):660-670.

Cornely OA et al. ESCMIID and ECMM joint clinical guidelines for the diagnosis and management of mucormycosis 2013. Clin Microbiol lnfect 2014;20 Suppl 3:5-26.

Chamilos G, Luna M, Lewis RE, Bodey GP, Chemaly R, Tarrand JJ, Safdar A, Raad II, Kontoyiannis DP. Invasive fungal infections in patients with hematologic malignancies in a tertiary care cancer center: an autopsy study over a 15-year peniod (1989- 2003). Haematologica 2006;91(7): 986- 989.

Dignani MC. Epidemiology ot invasive fungal diseases on the basis of autopsy reports. F1000Prime Rep 2014;6:81.

Spellberg B, Walsh TJ, Kontoyiannis DP et al. Recent advances in the management of mucormycosis: from bench to bedside. Clin Infect Dis. 2009;48(12):1743-1751.

Patterson TF, Thompson GR 3rd, Denning DW, Fishman JA, Hadley S, Herbrecht R, Kontoyiannis DP, Marr KA, Morrison VA, Nguyen MH, Segal BH, Steinbach WJ, Stevens DA, Walsh TJ, Wingard JR, Young JA, Bennett JE. Practice Guidelines for the Diagnosis and Management of
Aspergillosis: 2016 Update by the lnfectious Diseases Society of America. Clin lnfect Dis 2016;63(4):e1- 60.

Morace G, Borghi E. lnvasive mold infections: virulence and pathogenesis of mucorales. Int J Microbiol. 2012;1- 5.

Chakrabarti A, Chatterjee SS, Das A et al. lnvasive zygomycosis in lndia: experience in a tertiary care hospital. Postgrad Med J. 2009;85:573- 581.

Chamilos G et al. Delaying amphotericin B-based frontline therapy significantly increases rnortality among patients with hematologic malignancy who have zygomycosis. Clin lnfect Dis. 2008;47:503-9.

Pagano L et al. Risk assessment and prognostic factors for mould-related diseases in immuncompromised patients. J Antimicrob Chemother 2011;66 Suppll 1:i5-14.

Tsitsikas DA et al. Impact of the revised (2008) EORTC/MSG definitions for invasive fungal disease on the rates of diagnosis of invasive aspergillosis. Med Mycol 2012;50:538-42.

Walsh TJ et al. Treatment of Aspergillosis: Clinical. Abgerufen am 23.06.2026.

Roden MM et al. Epidemiology and Outcome of Zygornycosis: A Review of 929 Reported Cases. Clin lnfect Dis 2005;41:634-53.

Dimopoulos G et al. How to select an antifungal agent in critically ill patients. J Crit Care 2013;28:717-27.